---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053384"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2026-08-05T20:17:15+00:00"
generated_at: "2026-08-05T20:20:52.268102+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evolus Q2 revenue $84.1M (+21% YoY); raises FY2026 guidance; adds Profhilo U.S. rights

## Summary
- Q2 net revenue $84.1M (+21% YoY); GAAP operating loss $4.5M; adjusted EBITDA $4.7M (vs -$7.9M prior year).
- Raises FY2026 revenue guidance to $330-337M; raises adjusted gross margin to 67.0-67.5%; narrows non-GAAP opex to $212-216M.
- Exclusive U.S. partnership for Profhilo (IBSA); peak revenue >$100M; U.S. launch expected 2030.
- Expands Estyme HA gel franchise into Canada, Australia, New Zealand; commercialization expected 2028.
- Cash $45.2M; $120M non-dilutive capacity; reaffirms 2028 outlook ($450-500M revenue, 13-15% adj EBITDA margin).

## SEC filing metadata
- accession: 0001628280-26-053384
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2026-08-05T20:17:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/0001628280-26-053384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/eols-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053384
- JSON: https://secwatch.observer/filing/0001628280-26-053384.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.